



Translation

Notice: This document is a translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

July 11, 2025

To Whom It May Concern:

Company Name: Daito Pharmaceutical Co., Ltd.
Representative: Hiroshi Matsumori, President and CEO
(Securities Code: 4577, Prime Market of Tokyo Stock Exchange)
Inquiries: Kenji Otsuga, CFO
(Telephone Number: +81-76-421-5665)

[Machine Translation]

Notice Regarding Introduction of Shareholder Special Benefit Plan

Daito Pharmaceutical Co., Ltd. (the "Company") hereby announces that the Company resolved at a board meeting held on July 11, 2025 to introduce a shareholder special benefit plan as follows.

1. Purpose of introducing the shareholder special benefit plan

The company positions the sustainable growth of its enterprise value and stable returns to our shareholders as key management priorities. Starting with the medium-term management plan "DTP2027," announced last year, we have newly adopted the dividend on equity (DOE) as a dividend indicator. This reflects our commitment to a stable shareholder return policy that is not influenced by the profit levels of each individual fiscal year.

Additionally, to create an environment that makes it easier for investors to invest, improve the liquidity of our shares, and expand the investor base that resonates with our corporate philosophy and future growth strategies, we implemented a stock split (at a ratio of 2 shares for every 1 common share) effective June 1.

In this context, to further enhance the attractiveness of our shares as an investment option, to increase the number of shareholders who hold our shares over the medium to long term, and to express our gratitude for the continued support of our shareholders, we have decided to introduce the shareholder benefit program. This initiative also aims to contribute to the realization of a healthy and long-lived society, in line with our mission as a pharmaceutical company, by supporting the well-being and health of our shareholders.

2. Overview of the Shareholder Benefit Program

(1) Eligible Shareholders

Shareholders who have continuously held 100 or more shares of the company for at least six months as of the record dates (November 30 and May 31 each year) are eligible.

However, for the initial implementation of the shareholder benefits program, all shareholders holding 100 or more shares of the company as of the record date of November 30, 2025, will be eligible.

(2) Details of the Shareholder Benefits

Depending on the number of shares held and the holding period, shareholders will be able to purchase health supplements (developed by the company as a pharmaceutical company and manufactured by health supplement manufacturers, and currently sold through its distributors) at a 60% discount.

	November 30, 2025	From May 31, 2026, onwards
Continuous Holding Period	—	Six months or more
100 to 499 shares	Up to 1 item	Up to 1 item
500 shares or more	Up to 5 items	Up to 5 items

- To meet the continuous holding requirement, shareholders must appear in the shareholder registry under the same shareholder number for two consecutive record dates (November 30 and May 31).
- Discount coupons must be used within six months of issuance.

(3) Details of Eligible Health Supplement Products

As of today, the following seven types of products are eligible. Please note that the eligible products, prices, and specifications are subject to change in the future.

Product Name	Cassis Eye Power II	Hyaluron Q Plus III /	Q10 Prime
Product Category	Cassis Extract Processed Food	Hyaluronic Acid-Containing Processed Food	Coenzyme Q10-Containing Food
Volumes	90 cap. × 3	80 cap. × 3 320 cap. × 2	60 cap. × 2 240 cap. × 2
Retail Price (Excluding Tax):	20,400 JPY	24,000 JPY 58,000 JPY	13,000 JPY 46,000 JPY

Product Name	Lina Health Plus	Ginkgo Leaf Q	Lable Jelly II
Product Category	Spirulina Food	Ginkgo Leaf Extract Processed Food	Lable Bacteria-Containing Processed Food
Volumes	1,800 cap.	90 cap. × 3	30 pk. × 3
Retail Price (Excluding Tax):	10,000 JPY	21,000 JPY	11,700 JPY

Product Name	Prime Aojiru+ Vegetable Enzyme 108
Product Category	Barley Grass Powder Processed Food Nutritional Function Food (Vitamin B12)
Volumes	90 pk.
Retail Price (Excluding Tax):	8,000 JPY

(4) Timing of the Distribution

The shareholder benefit program will be based on the record dates of November 30 and May 31 each year, and the benefits will be shipped within approximately three months from the entitlement date. For the shareholder benefits based on the record date of November 30 this year, they are scheduled to be sent around the end of January 2026, enclosed with the "84th Interim Report" and other documents.

3. Others

If there are any changes to the details of the shareholder benefits program, we will notify you promptly.